Vardenafil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-9688

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 71335-9688). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula For Vardenafil Hydrochloride (Image 1)

Structural Formula For Vardenafil Hydrochloride (Image 1)
Chemical structure diagram of Vardenafil Hydrochloride as shown in the image, including molecular formula details and hydration state (x HCl x 3H2O).*
FDA Label Image

Figure 1: Placebo-subtracted Point Estimates (with 90% Ci) Of Mean Maximal Blood Pressure And Heart Rate Effects Of Pre-dosing With Vardenafil 20 mg At 24, 8, 4, And 1 Hour Before 0.4 mg Ntg Sublingually (Image 2)

Figure 1: Placebo-subtracted Point Estimates (with 90% Ci) Of Mean Maximal Blood Pressure And Heart Rate Effects Of Pre-dosing With Vardenafil 20 mg At 24, 8, 4, And 1 Hour Before 0.4 mg Ntg Sublingually (Image 2)
This figure presents three line graphs displaying the mean maximal change in systolic blood pressure, diastolic blood pressure, and heart rate over time (24h, 8h, 4h, 1h) following Vardenafil treatment prior to NTG administration. Each graph includes error bars indicating variability in measurements.*
FDA Label Image

Figure 2: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 5 mg Or Placebo With Stable Dose Tamsulosin 0.4 mg In Normotensive Bph Patients (study 1) (Image 3)

Figure 2: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 5 mg Or Placebo With Stable Dose Tamsulosin 0.4 mg In Normotensive Bph Patients (study 1) (Image 3)
A line graph depicting the mean change in mmHg over time (hours) for placebo and Vardenafil 5 mg under simultaneous and 8-hour separation conditions. The y-axis represents mean change in mmHg, ranging from -15 to 15, and the x-axis shows time from 0 to 6 hours. Four data series are plotted with distinct markers for each condition.*
FDA Label Image

Figure 3: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 5 mg Or Placebo With Stable Dose Terazosin (5 Or 10mg) In Normotensive Bph Patients (study 1) (Image 4)

Figure 3: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 5 mg Or Placebo With Stable Dose Terazosin (5 Or 10mg) In Normotensive Bph Patients (study 1) (Image 4)
A line graph displaying mean change in mmHg on the y-axis over time in hours on the x-axis, comparing effects of Vardenafil 5 mg and placebo under simultaneous and 8-hour separation conditions. Four data series are shown with different markers for each condition.*
FDA Label Image

Figure 4: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Administration Of Vardenafil 10 mg (stage 1), Vardenafil 20 mg (stage 2), Or Placebo With Stable Dose Tamsulosin 0.4 mg In Normotensive Bph Patients (study 2) (Image 5)

Figure 4: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Administration Of Vardenafil 10 mg (stage 1), Vardenafil 20 mg (stage 2), Or Placebo With Stable Dose Tamsulosin 0.4 mg In Normotensive Bph Patients (study 2) (Image 5)
A line graph displaying mean change in mmHg over time (hours) for placebo (Stage 1 and 2) and Vardenafil oral tablets at 10 mg and 20 mg doses. The graph shows decreasing blood pressure change over 6 hours with both Vardenafil doses compared to placebo stages.*
FDA Label Image

Figure 5: Mean Change From Base Line In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following 4 Hr Separation Administration Of Vardenafil 5 mg (stage 1), Vardenafil 10 mg (stage 2) Or Placbo With Stable Dose Alfuzosin 10 mg I Bph Patients (study 3) (Image 6)

Figure 5: Mean Change From Base Line In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following 4 Hr Separation Administration Of Vardenafil 5 mg (stage 1), Vardenafil 10 mg (stage 2) Or Placbo With Stable Dose Alfuzosin 10 mg I Bph Patients (study 3) (Image 6)
Line graph depicting mean change in mmHg over time in hours for placebo (stage 1 and 2) and Vardenafil 5 mg and 10 mg doses. The graph shows data points and trend lines for each group over a 6-hour period, illustrating changes in blood pressure or related metric.*
FDA Label Image

Figure 5: Man Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 10 mg, Vardenafil 20 mg Or Placebo With Terazosin (10 mg) In Healthy Volunteers (Image 7)

Figure 5: Man Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 10 mg, Vardenafil 20 mg Or Placebo With Terazosin (10 mg) In Healthy Volunteers (Image 7)
A line graph titled "TERAZOSIN" showing mean change in mmHg on the y-axis versus time in hours on the x-axis over a 6-hour period. The graph compares placebo, 10 mg Vardenafil, and 20 mg Vardenafil effects with two conditions: 6-hour separation and simultaneous administration, using distinct markers for each group.*
FDA Label Image

Figure 6: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 10 mg, Vardenafil 20 mg Or Placebo With Tamsulosin (0.4 mg) In Healthy Volunteers (Image 8)

Figure 6: Mean Change From Baseline In Standing Systolic Blood Pressure (mmhg) Over 6 Hour Interval Following Simultaneous Or 6 Hr Separation Administration Of Vardenafil 10 mg, Vardenafil 20 mg Or Placebo With Tamsulosin (0.4 mg) In Healthy Volunteers (Image 8)
A line graph titled 'TAMSULOSIN' showing mean change in mmHg blood pressure on the y-axis over time in hours on the x-axis. It compares placebo and Vardenafil at 10 mg and 20 mg doses, both with 6-hour separation and simultaneous administration, illustrating their effects on blood pressure over a 6-hour period.*
FDA Label Image

Figure 7: Plasma Vardenafil Concentration (mean Plus Or Minus Sd) Curve For A Single 20 mg Vardenafil Hydrochloride Dose (Image 9)

Figure 7: Plasma Vardenafil Concentration (mean Plus Or Minus Sd) Curve For A Single 20 mg Vardenafil Hydrochloride Dose (Image 9)
A line graph depicting plasma concentration (µg/L) over time (hours) following administration of Vardenafil Hydrochloride 20 mg film-coated tablets. The graph shows peak plasma concentration occurring around 1-2 hours post-dose, followed by a gradual decline over 24 hours. Error bars indicate variability at each time point.*
FDA Label Image

Label (Lbl713359688)

Label (Lbl713359688)
Label for Vardenafil Hydrochloride Tablets, 20 mg strength, oral film-coated tablets. The label indicates the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Rivopharm SA. The package contains 30 tablets with NDC 71335-9688-1. Storage instructions and warnings about keeping the drug out of reach of children are also noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.